The transcript of the chairman’s address to the Annual General Meeting of Shareholders, for the financial year ending December 2020, is now available.
Please click to review the transcript at ASX.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)